Search and analyze individual stocks with comprehensive metrics
Syncom Formulations India Ltd
Fundamental Score
Syncom Formulations India Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SYNCOMF across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (15.50%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.59%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 23.28 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (53.79%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (19.66%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (17.51% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (23.05% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (27.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (105.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (50.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-10.56 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 0.10%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Syncom Formulations India Ltd
About SYNCOMF
Business Overview
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
Company Details
Key Leadership
SYNCOMF Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Syncom Formulations India Ltd (SYNCOMF)?
As of 20 Jan 2026, 10:59 am IST, Syncom Formulations India Ltd (SYNCOMF) is currently trading at ₹12.16. The stock has a market capitalization of ₹1.46K (Cr).
Is SYNCOMF share price Overvalued or Undervalued?
SYNCOMF is currently trading at a P/E ratio of 23.28x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Syncom Formulations India Ltd share price?
Key factors influencing SYNCOMF's price include its quarterly earnings growth (Sales Growth: 19.66%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Syncom Formulations India Ltd a good stock for long-term investment?
Syncom Formulations India Ltd shows a 5-year Profit Growth of 27.71% and an ROE of 15.50%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Syncom Formulations India Ltd compare with its industry peers?
Syncom Formulations India Ltd competes with major peers in the Pharmaceuticals. Investors should compare SYNCOMF's P/E of 23.28x and ROE of 15.50% against the industry averages to determine its competitive standing.
What is the P/E ratio of SYNCOMF and what does it mean?
SYNCOMF has a P/E ratio of 23.28x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹23 for every ₹1 of annual earnings.
How is SYNCOMF performing according to Bull Run's analysis?
SYNCOMF has a Bull Run fundamental score of 62.3/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SYNCOMF belong to?
SYNCOMF operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Syncom Formulations India Ltd.
What is Return on Equity (ROE) and why is it important for SYNCOMF?
SYNCOMF has an ROE of 15.50%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Syncom Formulations India Ltd generates profits from shareholders' equity.
How is SYNCOMF's debt-to-equity ratio and what does it indicate?
SYNCOMF has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SYNCOMF's dividend yield and is it a good dividend stock?
SYNCOMF offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SYNCOMF grown over the past 5 years?
SYNCOMF has achieved 5-year growth rates of: Sales Growth 17.51%, Profit Growth 27.71%, and EPS Growth 23.05%.
What is the promoter holding in SYNCOMF and why does it matter?
Promoters hold 50.57% of SYNCOMF shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SYNCOMF's market capitalization category?
SYNCOMF has a market capitalization of ₹1463 crores, placing it in the Small-cap category.
How volatile is SYNCOMF stock?
SYNCOMF has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SYNCOMF?
SYNCOMF has a 52-week high of ₹N/A and low of ₹N/A.
What is SYNCOMF's operating profit margin trend?
SYNCOMF has a 5-year average Operating Profit Margin (OPM) of 11.41%, indicating the company's operational efficiency.
How is SYNCOMF's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 19.66% and YoY Profit Growth of 53.79%.
What is the institutional holding pattern in SYNCOMF?
SYNCOMF has FII holding of 0.10% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.